AR065348A1 - Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer - Google Patents
Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancerInfo
- Publication number
- AR065348A1 AR065348A1 ARP080100631A ARP080100631A AR065348A1 AR 065348 A1 AR065348 A1 AR 065348A1 AR P080100631 A ARP080100631 A AR P080100631A AR P080100631 A ARP080100631 A AR P080100631A AR 065348 A1 AR065348 A1 AR 065348A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- aryl
- cycloalkyl
- alkyl
- hydrogen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- -1 -S (O) nR4 Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composicion farmacéutica para uso en el tratamiento de un cáncer en mamíferos, que comprende un agonista no peptídico del receptor de TPO que es un compuesto que tiene la siguiente formula (1), en la que: cada uno de R, R1, R2 y R3 se seleccionaindependientemente entre hidrogeno, alquilo C1-6, -(CH2)pOR4, -C(O)OR4, formilo, nitro, ciano, halogeno, arilo, arilo sustituido, alquilo sustituido, -S(O)nR4, cicloalquilo, -NR5R6, -OH protegido, -CONR5R6, ácido fosfonico, ácido sulfonico, ácidofosfínico, -SO2NR5R6, y un sustituyente metileno heterocíclico como se representa por la formula (3), en la que, p es 0-6, n es 0-2, cada uno de V, W, X y Z se selecciona independientemente entre O, S y NR16, donde R16 se selecciona entre:hidrogeno, alquilo, cicloalquilo, arilo C1-12, alquilo sustituido, cicloalquilo sustituido y arilo C1-12 sustituido, R4 se selecciona entre: hidrogeno, alquilo, cicloalquilo, arilo C1-12, alquilo sustituido, cicloalquilo sustituido y arilo C1-12sustituido, y cada uno de R5 y R6 se selecciona independientemente entre hidrogeno, alquilo, alquilo sustituido, cicloalquilo C3-6 y arilo, o R5 y R6 tomados junto con el nitrogeno al que están unidos representan un anillo saturado de 5 a 6 miembrosque contiene hasta un heteroátomo más seleccionado entre oxigeno y nitrogeno; m es 0-6; y AR es un anillo aromático, cíclico o policíclico, que contiene de 3 a 16 átomos de carbono y que contiene opcionalmente uno o más heteroátomos, con lacondicion de que cuando el numero de átomos de carbono es 3, el anillo aromático contenga al menos dos heteroátomos y cuando el numero de átomos de carbono es 4, el anillo aromático contenga al menos un heteroátomo, y está opcionalmente sustituidocon uno o más sustituyentes seleccionados entre el grupo que consiste en: alquilo, alquilo sustituido, arilo, cicloalquilo sustituido, arilo sustituido, ariloxi, oxo, hidroxi, alcoxi, cicloalquilo, aciloxi, amino, N-acilamino, nitro, ciano,halogeno, -C(O)OR4, -C(O)NR10R11, -S(O)2NR10R11, -S(O)nR4 y -OH protegido, donde n es 0-2, R4 es hidrogeno, alquilo, cicloalquilo, arilo C1-12, alquilo sustituido, cicloalquilo sustituido y arilo C1-12 sustituido, y R10 y R11 son independientementehidrogeno, cicloalquilo, arilo C1-12, cicloalquilo sustituido, arilo C1-12 sustituido, alquilo o alquilo sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en: alcoxi, aciloxi, ariloxi, amino, N-acilamino, oxo, hidroxi,-C(O)OR4, -S(O)nR4, -C(O)NR4R4, -S(O)2NR4R4, nitro, ciano, cicloalquilo, cicloalquilo sustituido, halogeno, arilo, arilo sustituido y -OH protegido, o R10 y R11 tomados junto con el nitrogeno al que están unidos, representan un anillo saturado de 5a 6 miembros que contiene hasta un heteroátomo más seleccionado entre oxigeno y nitrogeno, donde R4 es como se ha descrito anteriormente y n es 0-2; y/o una sal farmacéuticamente aceptable, hidrato, solvato o éster del mismo; con la condicion de queal menos uno de R, R1, R2 y R3 sea un grupo arilo sustituido o un sustituyente metileno heterocíclico como se representa en la formula (3). Combinacion farmacéutica que la comprende junto con un agente anti-neoplásico. Uso de dicha composicion ycombinacion para la preparacion de un medicamento util para el tratamiento del cáncer. Reivindicacion 10: La combinacion de la reivindicacion 4, caracterizada porque dicho al menos un agente antineoplásico es paclitaxel, carboplatino ovinorelbina.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89023607P | 2007-02-16 | 2007-02-16 | |
| US89255207P | 2007-03-02 | 2007-03-02 | |
| US90820507P | 2007-03-27 | 2007-03-27 | |
| US94934707P | 2007-07-12 | 2007-07-12 | |
| US95228907P | 2007-07-27 | 2007-07-27 | |
| US96919207P | 2007-08-31 | 2007-08-31 | |
| US97721607P | 2007-10-03 | 2007-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065348A1 true AR065348A1 (es) | 2009-06-03 |
Family
ID=39690807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100631A AR065348A1 (es) | 2007-02-16 | 2008-02-14 | Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20100075928A1 (es) |
| EP (1) | EP2124547B3 (es) |
| JP (1) | JP5511391B2 (es) |
| KR (1) | KR101447763B1 (es) |
| CN (1) | CN101662937B (es) |
| AR (1) | AR065348A1 (es) |
| AU (1) | AU2008216106C1 (es) |
| BR (1) | BRPI0807940B8 (es) |
| CA (1) | CA2678358C (es) |
| CR (1) | CR10997A (es) |
| DK (1) | DK2124547T6 (es) |
| EA (1) | EA017715B1 (es) |
| ES (1) | ES2675070T7 (es) |
| FI (1) | FI2124547T4 (es) |
| HU (1) | HUE038563T2 (es) |
| IL (2) | IL200319A (es) |
| MA (1) | MA31202B1 (es) |
| MX (1) | MX2009008822A (es) |
| NZ (1) | NZ579068A (es) |
| PE (1) | PE20081784A1 (es) |
| PL (1) | PL2124547T5 (es) |
| PT (1) | PT2124547T (es) |
| SI (1) | SI2124547T2 (es) |
| TR (1) | TR201809010T4 (es) |
| TW (1) | TW200906393A (es) |
| UY (1) | UY30915A1 (es) |
| WO (1) | WO2008101141A2 (es) |
| ZA (1) | ZA200905532B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| CA2709224C (en) * | 2007-10-09 | 2015-06-23 | The Trustees Of The University Of Pennsylvania | Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells |
| AU2010254046C1 (en) | 2009-05-29 | 2014-03-06 | Novartis Ag | Methods of administration of thrombopoietin agonist compounds |
| AU2011296047A1 (en) * | 2010-09-01 | 2013-03-21 | Novartis Ag | Combination of HDAC inhibitors with thrombocytopenia drugs |
| WO2014150252A1 (en) * | 2013-03-15 | 2014-09-25 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
| ES2940227T3 (es) * | 2016-05-06 | 2023-05-04 | Taris Biomedical Llc | Método de tratamiento del cáncer urotelial del tracto inferior |
| RU2675695C1 (ru) * | 2018-03-06 | 2018-12-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Способ лечения рака предстательной железы высокого и очень высокого риска |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| US6316652B1 (en) * | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| AU9265698A (en) | 1997-09-02 | 1999-03-22 | Boehringer Mannheim Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia |
| AU6023300A (en) * | 1999-07-26 | 2001-02-13 | Shionogi & Co., Ltd. | Drug compositions exhibiting thrombopoietin agonism |
| EP1104674A1 (de) | 1999-11-10 | 2001-06-06 | Curacyte AG | O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung |
| ES2528307T3 (es) * | 1999-11-10 | 2015-02-06 | Innatus Corporation | Método y sistema para eliminar el inhibidor de citoquina en pacientes |
| TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| AU2001260661A1 (en) | 2000-05-30 | 2001-12-11 | Chugai Seiyaku Kabushiki Kaisha | Compounds exhibiting thrombopoietin-like activities |
| WO2001092306A2 (en) * | 2000-05-31 | 2001-12-06 | Genzyme Corporation | Therapeutic compounds for ovarian cancer |
| JP4458746B2 (ja) * | 2001-01-16 | 2010-04-28 | グラクソ グループ リミテッド | 癌の治療方法 |
| JP4145654B2 (ja) | 2001-01-26 | 2008-09-03 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有する環状化合物 |
| JP4145655B2 (ja) | 2001-01-26 | 2008-09-03 | 塩野義製薬株式会社 | トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物 |
| JPWO2002062775A1 (ja) | 2001-02-02 | 2004-06-10 | 山之内製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| EP1435963A4 (en) * | 2001-09-24 | 2005-10-26 | Tosk Inc | CISPLATIN FORMULATIONS WITH REDUCED TOXICITY AND USE METHOD THEREFOR |
| DK1466912T3 (da) | 2002-01-18 | 2013-07-01 | Astellas Pharma Inc | 2-acylaminothiazolderivat eller salt deraf |
| MY142390A (en) * | 2002-05-22 | 2010-11-30 | Glaxosmithkline Llc | 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| AU2003268687A1 (en) | 2002-09-30 | 2004-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel salt of 2-acylaminothiazole derivative |
| EP2387998A1 (en) | 2003-04-29 | 2011-11-23 | Glaxosmithkline LLC | Methods for treating degenerative diseases/injuries |
| WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| AU2005299720B2 (en) * | 2004-10-25 | 2010-02-04 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
| AU2006318527A1 (en) | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Incorporated | Thrombopoietin activity modulating compounds and methods |
| JP2009530297A (ja) | 2006-03-15 | 2009-08-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | トロンボポエチン活性調節化合物の合成 |
-
2008
- 2008-02-13 UY UY30915A patent/UY30915A1/es unknown
- 2008-02-14 PE PE2008000322A patent/PE20081784A1/es not_active Application Discontinuation
- 2008-02-14 AR ARP080100631A patent/AR065348A1/es not_active Application Discontinuation
- 2008-02-14 TW TW097105201A patent/TW200906393A/zh unknown
- 2008-02-15 AU AU2008216106A patent/AU2008216106C1/en active Active
- 2008-02-15 SI SI200831968T patent/SI2124547T2/sl unknown
- 2008-02-15 KR KR1020097019224A patent/KR101447763B1/ko active Active
- 2008-02-15 DK DK08729939.2T patent/DK2124547T6/da active
- 2008-02-15 NZ NZ579068A patent/NZ579068A/en not_active IP Right Cessation
- 2008-02-15 CN CN200880012425.7A patent/CN101662937B/zh active Active
- 2008-02-15 EP EP08729939.2A patent/EP2124547B3/en active Active
- 2008-02-15 HU HUE08729939A patent/HUE038563T2/hu unknown
- 2008-02-15 PT PT87299392T patent/PT2124547T/pt unknown
- 2008-02-15 CA CA2678358A patent/CA2678358C/en active Active
- 2008-02-15 EA EA200970776A patent/EA017715B1/ru not_active IP Right Cessation
- 2008-02-15 WO PCT/US2008/054046 patent/WO2008101141A2/en not_active Ceased
- 2008-02-15 TR TR2018/09010T patent/TR201809010T4/tr unknown
- 2008-02-15 BR BRPI0807940A patent/BRPI0807940B8/pt active IP Right Grant
- 2008-02-15 ES ES08729939T patent/ES2675070T7/es active Active
- 2008-02-15 PL PL08729939.2T patent/PL2124547T5/pl unknown
- 2008-02-15 JP JP2009550145A patent/JP5511391B2/ja active Active
- 2008-02-15 US US12/527,220 patent/US20100075928A1/en not_active Abandoned
- 2008-02-15 MX MX2009008822A patent/MX2009008822A/es active IP Right Grant
- 2008-02-15 FI FIEP08729939.2T patent/FI2124547T4/fi active
- 2008-07-02 US US12/166,686 patent/US20090022814A1/en not_active Abandoned
-
2009
- 2009-08-07 ZA ZA200905532A patent/ZA200905532B/xx unknown
- 2009-08-10 IL IL200319A patent/IL200319A/en active IP Right Grant
- 2009-08-26 CR CR10997A patent/CR10997A/es not_active Application Discontinuation
- 2009-08-31 MA MA32188A patent/MA31202B1/fr unknown
-
2015
- 2015-04-20 IL IL238394A patent/IL238394B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065348A1 (es) | Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| CO2023003282A2 (es) | Nuevos derivados de psilocina que tienen propiedades de profármaco | |
| AR030696A1 (es) | Derivados de hidroxi-1-azobenceno, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, proceso para preparar dichas composiciones, proceso para preparar dichos compuestos, metodo in vitro o ex vivo para aumentar la estimulacion de la maduracion | |
| PA8785401A1 (es) | Derivados de bencimidazol | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| DOP2007000022A (es) | Derivados de n-heteroaril-carboxamidas tricíclicas que contienen un resto bencimidazol, su preparación y su aplicación en terapéutica | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| MX384744B (es) | Derivado de morfinano. | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| MX391096B (es) | Formulación liposomal. | |
| AR046170A1 (es) | Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| PE20220169A1 (es) | Compuestos macrociclicos como agonistas de sting | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |